OUR APPROACH
WHAT WE DO
RESEARCH
DRUG PROGRAMMES
DRUG PROGRAMMES
COVID-19
ATOPIC DERMATITIS
ULCERATIVE COLITIS
PARTNERING
COLLABORATIONS
LICENSING
CASE STUDIES
investors
CORPORATE OVERVIEW
PRESS RELEASES
INVESTOR PRESENTATIONS
BUSINESS COMBINATION
CORPORATE GOVERNANCE
INVESTORS RESOURCES
EMAIL ALERTS
ABOUT US
ABOUT US
LEADERSHIP
AI PRINCIPLES
CONTACT US
OFFICES
JOIN US
WORKING AT BENEVOLENT
FIND A JOB
INTERNSHIPS
CULTURE BLOG
News & MEDIA
News
Notifications of persons discharging managerial responsabilities
May 5, 2022
Home
NEWS
News
Notifications of persons discharging managerial responsabilities
Tagged:
Press Release
Link to pdf →
Receive our latest news
Featured Posts
News
RECOVERY trial results demonstrate baricitinib reduces deaths in hospitalised COVID-19 patients
Blog
World Health Organization panel strongly recommends the use of baricitinib to treat hospitalised patients with COVID-19
News
BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure
Follow us
More Posts
You Might Also Like
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
PDMR Notification (Dr. Olivier Brandicourt)
May 5, 2022
News
PDMR Notification (Jean Raby)
May 5, 2022
News
Notifications of Major Holdings
Apr 29, 2022
News
ANNEX A: Standard form for notification of major holdings
Apr 29, 2022
